



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: eplerenone

Brand Name: Inspra

Medication Class: Selective aldosterone receptor antagonist

FDA Approved Uses: mild to moderate hypertension
Congestive heart failure post-myocardial infarction

Usual Dose: HTN- 50-100mg/day (50mg starting dose)
CHF- 25-50mg/day (25 mg starting dose)

Duration of Therapy: indefinite

Criteria for Use (HTN): *(bullet points below are all inclusive unless otherwise noted)*

- Failed/intolerant to therapy with at least 2 alternative formulary medications including; diuretics, beta blockers, calcium channel blockers, ACE inhibitors, ARBs, spironolactone.
- Documented mild-moderate hypertension
- Document of recent potassium and serum creatinine levels.
 - Serum potassium must be <5.5 mEq/L at initiation.
 - Serum creatinine must be <2.0 mg/dl in males and <1.8 mg/dl in females.
 - Creatinine clearance must be >50 ml/min at initiation.

Criteria for Use (CHF): *(bullet points below are all inclusive unless otherwise noted)*

- Clinically documented CHF post MI
- Currently receiving standard care with ACE inhibitors and beta blockers.
- Failed/intolerant to spironolactone and at least 1 other formulary alternative medication of the following classes/drug: diuretics, digoxin, ARBs.
- Left ventricular ejection fraction (LVEF) \leq 40%.
- Documentation of recent potassium and serum creatinine levels.
 - Serum potassium must be <5.5 mEq/L at initiation.
 - Creatinine clearance must be >30 ml/min at initiation.

Contraindications:

- Serum potassium >5.5mEq/L at initiation.
- Creatinine clearance \leq 30ml/min.
- Concomitant use with ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, or any drug that is a potent CYP3A4 inhibitor.



- Concomitant use of potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene).
- For patients with hypertension, Inspra is also contraindicated in the following:(for patients with CHF they should be treated with caution in the following)
 - Type 2 Diabetes and microalbuminuria.
 - Serum creatinine >2.0 mg/dl in males and 1.8 mg/dl in females.
 - Creatinine clearance <50 ml/min.

Not approved if:

- Patient has any contraindications to the use of Inspra.

P&T Approval: _____ Date: _____